J. Kornej, C. S. Börschel, E. J. Benjamin, and R. B. Schnabel, “Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights,” Circ. Res., 127, No. 1, 4–20 (2020); doi:https://doi.org/10.1161/CIRCRESAHA.120.316340.
CAS Article PubMed PubMed Central Google Scholar
2.А. M. Alshehri, “Stroke in atrial fibrillation: review of risk stratification and preventive therapy,” J. Family Community Med., 26, No. 2, 92–97 (2019); doi:https://doi.org/10.4103/jfcm.JFCM_99_18.
Article PubMed PubMed Central Google Scholar
3.D. A. Dulli, H. Stanko, and R. L. Levine, “Atrial fibrillation is associated with severe acute ischemic stroke,” Neuroepidemiology, 22, No. 2, 118–123 (2003); doi: https://doi.org/10.1159/000068743.
4.E. S. Donkor, “Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life,” Stroke Res. Treat., 2018, 3238165, (2018); doi:https://doi.org/10.1155/2018/3238165.
Article PubMed PubMed Central Google Scholar
5.R. L. Jayaraj, S. Azimullah, R. Beiram, et al., “Neuroinflammation: friend and foe for ischemic stroke,” J. Neuroinflammation, 16, No. 1, 142 (2019); doi: https://doi.org/10.1186/s12974-019-1516-2.
6.Н. Stefansdottir, D. O. Arnar, T. Aspelund, et al., “Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts,” Stroke, 44, No. 4, 1020–1025 (2013); doi:https://doi.org/10.1161/STROKEAHA.12.679381.
Article PubMed PubMed Central Google Scholar
7.A. Saglietto, M. Matta, F. Gaita, et al., “Stroke-indepen-dent contribution of atrial fibrillation to dementia, a meta-analysis,” Open Heart, 6, No. 1, e000984 (2019); doi: https://doi.org/10.1136/openhrt-2018-000984.
8.М. Gardarsdottir, S. Sigurdsson, T. Aspelund, et al., “Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion,” Europace, 20, No. 8, 1252–1258 (2018); doi:https://doi.org/10.1093/europace/eux220.
9.R. N. Kalaria, “Risk factors and neurodegenerative mechanisms in stroke related dementia,” Panminerva Med., 54, No. 3, 139–148 (2012).
10.T. A. Manolis, A. A. Manolis, E. J. Apostolopoulos, et al., “Atrial fibrillation and cognitive impairment: an associated burden or burden by association?,” Angiology, 71, No. 6, 498–519 (2020); doi:https://doi.org/10.1177/0003319720910669.
11.R. M. Ferreira Lisboa Da Silva, C. Madeira Miranda, T. Liu, et al., “Atrial fibrillation and risk of dementia: epidemiology, mechanisms, and effect of anticoagulation,” Front. Neurosci., 13, Article 18, 1–7 (2019); doi:https://doi.org/10.3389/fnins.2019.00018.
12.P. Jasielski, F. Piędel, M. Piwek, et al., “Application of citicoline in neurological disorders: a systematic re- view,” Nutrients, 12, No. 10, 3113 (2020); doi: https://doi.org/10.3390/nu12103113.
13.L. F. Borkenhagen and E. P. Kennedy, “The enzymatic synthesis of cytidine diphosphate choline,” J. Biol. Chem., 227, No. 2, 951–962 (1957).
14.J. J. Secades, J. Alvarez-Sabín, J. Castillo, et al., “Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials,” J. Stroke Cerebrovasc Dis., 25, No. 8, 1984–1996 (2016); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010.
15.O. Y. Glushakova, A. V. Glushakov, E. R. Miller, et al., “Biomarkers for acute diagnosis and management of stroke in neurointensive care units,” Brain Circ., 2, No. 1, 28–47 (2016); doi:https://doi.org/10.4103/2394-8108.178546.
Article PubMed PubMed Central Google Scholar
16.G. C. Jickling and F. R. Sharp, “Blood biomarkers of ischemic stroke,” Neurotherapeutics, 8, No. 3, 349–360 (2011); doi: https://doi.org/10.1007/s13311-011-0050-4.
CAS Article PubMed PubMed Central Google Scholar
17.М. Khalil, С. Е. Teunissen, М. Otto, et al., “Neurofilaments as biomarkers in neurological disorders,” Nat. Rev. Neurol., 14, No. 10, 577–589 (2018); doi: https://doi.org/10.1038/s41582-018-0058-z.
CAS Article PubMed Google Scholar
18.Y. Lee, B. H. Lee, W. Yip, et al., “Neurofilament proteins as prognostic biomarkers in neurological disorders,” Curr. Pharm. Des., 25, No. 43, 4560–4569 (2020); doi: https://doi.org/10.2174/1381612825666191210154535.
CAS Article PubMed Google Scholar
19.Z. Yang and K. K. Wang, “Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker,” Trends Neurosci., 38, No. 6, 364–374 (2015); doi:https://doi.org/10.1016/j.tins.2015.04.003
CAS Article PubMed PubMed Central Google Scholar
20.Y. Wang, G. Liu, D. Hong, et al., “White matter injury in ischemic stroke,” Prog. Neurobiol., 141, 45–60 (2016); doi:https://doi.org/10.1016/j.pneurobio.2016.04.005.
Article PubMed PubMed Central Google Scholar
21.N. Wąsik, B. Sokół, M. Hołysz, et al., “Serum myelin basic protein as a marker of brain injury in aneurysmal subarachnoid haemorrhage,” Acta Neurochir. (Wien), 162, No. 3, 545–552 (2020); doi: https://doi.org/10.1007/s00701-019-04185-9.
22.J. Lee, G. Hamanaka, E. H. Lo, et al., “Heterogeneity of microglia and their differential roles in white matter pathology,” CNS Neurosci. Ther., 25, No. 12, 1290–1298 (2019); doi:https://doi.org/10.1111/cns.13266.
Article PubMed PubMed Central Google Scholar
23.S. Xu, J. Lu, A. Shao, et al., “Glial cells: role of the immune response in ischemic stroke,” Front. Immunol., 11, 294 (2020); doi:https://doi.org/10.3389/fimmu.2020.00294.
CAS Article PubMed PubMed Central Google Scholar
24.Y. Sasaki, K. Ohsawa, H. Kanazawa, et al., “Iba1 is an actin-cross-linking protein in macrophages/microglia,” Biochem. Biophys. Res. Commun., 286, No. 2, 292–297 (2001); doi:https://doi.org/10.1006/bbrc.2001.5388.
CAS Article PubMed Google Scholar
25.A. D. Lafrenaye, S. Mondello, K. K. Wang, et al., “Circulating GFAP and Iba-1 levels are associated with pathophysiological sequelae in the thalamus in a pig model of mild TBI,” Sci. Rep., 10, No. 1, 13369 (2020); doi:https://doi.org/10.1038/s41598-020-70266-w.
26.“Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS),” Eur. Heart J., 42, No. 5, 507 (2020); doi: https://doi.org/10.1093/eurheartj/ehaa798.
27.G. Montalescot, U. Sechtem, S. Achenbach, et al., “2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology,” Eur. Heart J., 34, No. 38, 2949–3003 (2013). doi: https://doi.org/10.1093/eurheartj/eht296.
28.W. J. Powers, A. A. Rabinstein, T. Ackerson, et al., “Gui-delines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 Guidelines for the early management of acute ischemic stroke: A Guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, 50, No. 12, e344–e418 (2019); doi.org/10.1161/STR.0000000000000211.
29.C. M. Stoscheck, “Quantitation of protein,” Methods Enzymol., 182, 50–68 (1990); doi: https://doi.org/10.1016/0076-6879(90)82008-p.
CAS Article PubMed Google Scholar
30.X. Yi, J. Lin, Z. Han, et al., “Preceding antithrombotic treatment is associated with acute ischemic stroke severity and functional outcome at 90 days among patients with atrial fibrillation,” J. Stroke. Cerebrovasc. Dis., 28, No. 7, 2003–2010 (2019); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.028.
31.Y. D. Cheng, L. Al-Khoury, and J. A. Zivin, “Neuroprotection for ischemic stroke: two decades of success and failure,” NeuroRx., 1, No. 1, 36–45 (2004); doi:https://doi.org/10.1602/neurorx.1.1.36.
32.M. Y. Martynov and E. I. Gusev, “Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke,” J. Exp. Pharmacol., 7, 17–28 (2015); doi:https://doi.org/10.2147/JEP.S63544.
CAS Article PubMed PubMed Central Google Scholar
33.J. J. Secades, “Citicoline: pharmacological and clinical review, 2016 update,” Rev. Neurol., 63, No. S03, S1–S73 (2016).
34.W. M. Clark, “Efficacy of citicoline as an acute stroke treatment,” Expert Opin. Pharmacother., 10, No. 5, 839–846 (2009); doi:https://doi.org/10.1517/17460440902835475.
CAS Article PubMed Google Scholar
35.K. Overgaard, “The effects of citicoline on acute ischemic stroke: a review,” J. Stroke. Cerebrovasc. Dis., 23, No. 7, 1764–1769 (2014); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.01.020.
36.J. Alvarez-Sabín and G. C. Román, “Citicoline in vascular cognitive impairment and vascular dementia after stroke,” Stroke, 42, No. 1, 40–43 (2011); doi:https://doi.org/10.1161/STROKEAHA.110.606509.
37.P. Deb, S. Sharma and K. M Hassan, “Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis,” Pathophysiology, 17, No. 3, 197–218 (2010); doi:https://doi.org/10.1016/j.pathophys.2009.12.001.
CAS Article PubMed Google Scholar
38.A. A. Tykhomyrov, Y. S. Kushnir, V. S. Nedzvetsky, et al., “Citicoline affects serum angiostatin and neurospecific protein levels in patients with atrial fibrillation and ischemic stroke,” Ukr. Biochem. J., 91, No. 5, 34–45 (2019); doi: https://doi.org/10.15407/ubj91.05.034.
39.T. Matsunaga, D. W. Weihrauch, M. C. Moniz, et al., “Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide,” Circulation, 105, No. 18, 2185–2191 (2002); doi:https://doi.org/10.1161/01.cir.0000015856.84385.e9.
CAS Article PubMed Google Scholar
40.J. Krupinski, M. Abudawood, S. Matou-Nasri, et al., “Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1,” Vasc. Cell, 4, No. 1, 20 (2012); doi: https://doi.org/10.1186/2045-824X-4-20.
41.H. H. Nielsen, S. B. Soares, S. S. Høgedal, et al., “Acute neurofilament light chain plasma levels correlate with stroke severity and clinical outcome in ischemic stroke patients,” Front. Neurol., 11, 448 (2020); doi:https://doi.org/10.3389/fneur.2020.00448.
Article PubMed PubMed Central Google Scholar
42.S. Köhler, U. Winkler, and J. Hirrlinger, “Heterogeneity of astrocytes in grey and white matter,” Neurochem. Res., 46, No. 1, 3–14 (2021); doi: https://doi.org/10.1007/s11064-019-02926-x.
CAS Article PubMed Google Scholar
43.A. Yuan, M. V. Rao, Veeranna, and R. A. Nixon, “Neurofilaments and neurofilament proteins in health and disease,” Cold Spring Harb. Perspect. Biol., 9, No. 4, a018309 (2017); doi:https://doi.org/10.1101/cshperspect.a018309.
44.S. Tiedt, M. Duering, C. Barro, et al., “Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke,” Neurology, 91, No. 14, e1338–e1347 (2018); doi:https://doi.org/10.1212/WNL.0000000000006282.
CAS Article PubMed Google Scholar
45.J. Cooper, S. Stukas, P. L. Hoiland, et al., “Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019,” Crit. Care. Explor., 2, No. 10, e0238 (2020); doi:https://doi.org/10.1097/CCE.0000000000000238.
46.Y. Zang, A. Liu, and L. Qi “The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum GFAP and copeptin level,” Eur. J. Inflam., 17, 1–8 (2019); https://doi.org/https://doi.org/10.1177/2058739219867244.
47.M. Y. Khodanovich, A. A. Kisel, A. E. Akulov, et al., “Quantitative assessment of demyelination in ischemic stroke in vivo using macromolecular proton fraction mapping,” J. Cereb. Blood Flow. Metab., 38, No. 5, 919–931 (2018); doi:https://doi.org/10.1177/0271678X18755203.
Comments (0)